Osteoporosis
While the epidemiology of ONJ in patients treated with bisphosphonates for malignancy is becoming clearer, this is certainly not the case with respect to patients with osteoporosis. In the literature survey carried out as part of the recent report from the American Society for Bone and Mineral Research [3], 57 reports were found. In the risedronate and alendronate clinical trial programs (each involving 16,000–17,000 patients), no cases of ONJ were noted. Post-marketing surveys to mid-2007 indicate an incidence of <1.2 per 100,000 patient-years for risedronate and of <0.5–2.5 per 100,000 patient-years for alendronate.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s00256-008-0549-x.
Rights and permissions
About this article
Cite this article
Reid, I.R., Cundy, T. Erratum to: Osteonecrosis of the jaw. Skeletal Radiol 38, 107 (2009). https://doi.org/10.1007/s00256-008-0596-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00256-008-0596-3